Gabon
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 9.13 (7.43 - 11.15) | 2015 | Modelled | WHO |
| 5.1 (3.20 - 6) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
| 11.48 (10.72 - 12.30) | 2013 | Modelled | Schweitzer et al, 2015 |
| 5.21 (4.74 - 5.74) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 5.68 (5.22 - 6.15) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.82 (5.34 - 6.32) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.97 (5.51 - 6.45) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.16 (5.64 - 6.69) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.35 (5.81 - 6.90) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.55 (6.01 - 7.13) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.76 (6.18 - 7.36) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.95 (6.33 - 7.61) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.12 (6.47 - 7.83) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.29 (6.64 - 7.98) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.46 (6.80 - 8.17) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.64 (6.97 - 8.37) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.81 (7.11 - 8.57) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.95 (7.23 - 8.75) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.08 (7.37 - 8.82) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.21 (7.50 - 8.93) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.34 (7.63 - 9.08) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.47 (7.75 - 9.24) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.58 (7.86 - 9.36) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.7 (7.96 - 9.46) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.83 (8.07 - 9.59) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.97 (8.18 - 9.75) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.12 (8.29 - 9.94) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.27 (8.40 - 10.13) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.44 (8.57 - 10.31) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.61 (8.77 - 10.50) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.8 (8.95 - 10.69) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10 (9.13 - 10.93) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.21 (9.33 - 11.19) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.5 (5 - 6.06) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Children under-5 years
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 4.16 (2.99 - 5.67) | 2015 | Modelled | WHO |
| 1.21 (0.95 - 1.51) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 1.34 (1.07 - 1.68) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.43 (1.13 - 1.78) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.51 (1.17 - 1.89) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.56 (1.23 - 1.94) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.62 (1.27 - 2.04) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.73 (1.37 - 2.16) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.89 (1.49 - 2.34) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.08 (1.65 - 2.58) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.31 (1.83 - 2.88) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.55 (2.02 - 3.22) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.85 (2.26 - 3.54) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.21 (2.56 - 3.98) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.63 (2.91 - 4.48) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.07 (3.23 - 5.04) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.5 (3.59 - 5.63) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.98 (3.96 - 6.16) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.52 (4.42 - 6.76) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.04 (4.83 - 7.36) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.48 (5.18 - 7.92) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.78 (5.40 - 8.36) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.95 (5.53 - 8.50) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.08 (5.65 - 8.60) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.18 (5.73 - 8.75) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.29 (5.79 - 8.92) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.41 (5.87 - 9.18) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.56 (5.99 - 9.30) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.73 (6.13 - 9.46) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.9 (6.31 - 9.74) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.08 (6.48 - 9.88) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.27 (6.65 - 10.23) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.12 (1.78 - 2.48) | 2020 | Modelled | WHO |
Showing out of
Show more
Number of persons living with chronic HBV
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 101,000 (63,000 - 118,000) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
| 91,259 (82,909 - 100,398) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 94,265 (85,821 - 103,587) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 95,705 (87,892 - 103,700) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 96,512 (88,485 - 104,736) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 97,481 (89,882 - 105,411) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 98,960 (90,733 - 107,513) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 100,259 (91,884 - 109,092) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 101,722 (93,217 - 110,965) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 103,135 (94,374 - 112,325) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 104,288 (94,975 - 114,012) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 104,975 (95,392 - 115,250) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 105,500 (96,232 - 115,595) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 106,162 (96,813 - 116,453) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 106,765 (97,624 - 117,047) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 107,129 (97,678 - 117,419) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 107,092 (97,390 - 117,831) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 106,854 (97,444 - 116,493) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 106,649 (97,224 - 115,945) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 106,380 (97,302 - 115,898) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 105,977 (97,018 - 115,794) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 105,362 (96,478 - 115,079) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 104,643 (95,856 - 113,823) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 103,971 (95,043 - 112,892) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 103,332 (94,304 - 112,372) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 102,725 (93,436 - 112,093) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 102,132 (92,683 - 111,704) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 101,570 (92,314 - 110,965) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 101,065 (92,156 - 110,347) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 100,599 (91,917 - 109,518) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 100,167 (91,523 - 109,669) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 99,761 (91,065 - 109,358) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 6.34 (4.07 - 9.48) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 10.62 (7.20 - 14.79) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.54 (7.18 - 14.59) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.41 (7.13 - 14.38) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.15 (6.97 - 13.87) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.13 (6.98 - 13.93) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.29 (7.07 - 14.21) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.21 (7.07 - 14.06) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.05 (6.99 - 13.79) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.63 (6.85 - 13.23) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.89 (6.94 - 13.59) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.61 (6.82 - 13.32) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.62 (6.75 - 13.35) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.36 (6.73 - 12.83) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.29 (6.67 - 12.94) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.88 (6.33 - 12.35) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.1 (6.49 - 12.57) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.91 (6.34 - 12.35) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.88 (6.32 - 12.38) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.89 (6.30 - 12.65) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.74 (6.11 - 12.44) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.49 (5.84 - 12.13) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.33 (5.78 - 11.93) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.02 (5.54 - 11.55) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.64 (5.28 - 11.04) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.3 (4.95 - 10.55) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.03 (4.72 - 10.23) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.77 (4.47 - 9.88) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.59 (4.28 - 9.68) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.34 (4.07 - 9.48) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.42 (4.17 - 9.44) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 186 | 2016 | Modelled | WHO |
| 105 (71 - 147) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 107 (73 - 148) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 109 (74 - 150) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 108 (74 - 148) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 111 (76 - 152) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 115 (79 - 159) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 117 (81 - 161) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 118 (82 - 161) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 118 (83 - 163) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 118 (84 - 162) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 120 (84 - 167) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 122 (87 - 169) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 122 (87 - 166) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 123 (88 - 171) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 123 (88 - 170) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 127 (90 - 177) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 124 (89 - 173) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 122 (87 - 170) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 129 (92 - 184) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 129 (90 - 184) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 128 (88 - 182) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 125 (86 - 180) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 128 (88 - 183) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 121 (84 - 175) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 115 (77 - 168) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 118 (80 - 170) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 113 (75 - 165) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 112 (72 - 164) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 111 (72 - 163) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 111 (71 - 166) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 111 (71 - 166) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
Download
Showing out of
Show more
Coverage of 3-dose hepatitis B vaccine
Infants
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 70 | 2019 | Survey/reported | WHO/UNICEF |
| 63 | 2020 | Survey/reported | WHO/UNICEF |
| 75 | 2021 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 0 (0 - 0) | 2016 | Survey/reported | Harm Reduction International, 2016 |
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0 | 2016 | Survey/reported | Harm Reduction International, 2016 |
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
No
Eligible for HBV generic medicines
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 7 (5.10 - 7.30) | 2015 | Modelled | Blach et al, 2017 |
| 3.74 (3.06 - 4.64) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.76 (3.08 - 4.63) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.76 (3.07 - 4.63) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.76 (3.08 - 4.66) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.77 (3.06 - 4.68) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.79 (3.09 - 4.66) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.82 (3.15 - 4.63) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.86 (3.21 - 4.65) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.91 (3.28 - 4.68) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.95 (3.30 - 4.71) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.01 (3.36 - 4.77) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.1 (3.45 - 4.83) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.19 (3.53 - 4.95) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.28 (3.60 - 5.07) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.34 (3.64 - 5.15) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.39 (3.70 - 5.21) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.44 (3.76 - 5.26) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.48 (3.79 - 5.32) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.52 (3.81 - 5.36) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.56 (3.86 - 5.39) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.59 (3.86 - 5.46) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.61 (3.84 - 5.53) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.62 (3.79 - 5.60) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.64 (3.79 - 5.70) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.68 (3.78 - 5.83) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.74 (3.83 - 5.91) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.81 (3.88 - 6) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.88 (3.93 - 6.08) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.96 (4 - 6.20) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5.05 (4.09 - 6.29) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.64 (2.98 - 4.51) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Women of childbearing age (15–49 years)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 4.26 (3.09 - 4.41) | 2019 | Modelled | Dugan et al., 2021 |
Prevalence of anti-HCV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 11.2 (2.10 - 20.70) | 2014 | Survey/reported | Gower et al, 2014 |
Number of persons living with chronic HCV (RNA+/cAg)
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 124,000 (90,000 - 129,000) | 2015 | Modelled | Blach et al, 2017 |
| 49,348 (39,952 - 61,477) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 49,666 (40,043 - 61,974) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 50,063 (40,347 - 62,457) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 50,523 (40,810 - 62,954) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 51,007 (41,154 - 63,652) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 51,514 (41,652 - 64,075) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 52,239 (42,618 - 64,155) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 53,198 (43,682 - 64,521) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 54,258 (45,176 - 64,892) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 55,236 (46,432 - 65,576) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 55,987 (47,286 - 66,253) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 56,613 (47,750 - 66,982) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 57,168 (48,329 - 67,759) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 57,664 (48,753 - 68,301) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 58,089 (48,910 - 68,968) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 58,495 (49,056 - 69,520) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 58,726 (49,273 - 69,796) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 58,589 (49,292 - 69,227) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 58,294 (49,056 - 68,783) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 58,070 (48,755 - 68,990) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 58,210 (48,584 - 69,395) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 58,615 (49,108 - 70,289) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 58,943 (48,920 - 71,034) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 59,299 (48,896 - 72,055) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 59,780 (48,886 - 73,605) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 60,508 (48,921 - 75,119) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 61,435 (50,186 - 76,107) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 62,383 (51,092 - 76,960) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 63,292 (51,942 - 78,169) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 63,716 (52,158 - 78,876) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 64,129 (52,537 - 79,354) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Women of childbearing age (15–49 years)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 23,100 (16,700 - 23,900) | 2019 | Modelled | Dugan et al., 2021 |
HCV-related death rate
National
Download| Value (Deaths per 100,000) | Year | Type | Source |
|---|---|---|---|
| 8.33 (5.39 - 11.70) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 9.99 (7.08 - 13.73) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.9 (7.04 - 13.56) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.77 (7.03 - 13.40) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.54 (6.85 - 12.99) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.51 (6.76 - 12.92) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.63 (6.84 - 13.12) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.56 (6.86 - 12.84) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.39 (6.81 - 12.65) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.24 (6.72 - 12.49) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.02 (6.51 - 12.09) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.01 (6.50 - 12.15) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.01 (6.41 - 12.16) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.81 (6.35 - 11.89) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.78 (6.20 - 11.95) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.64 (6.12 - 11.93) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.41 (5.97 - 11.72) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.46 (6.01 - 11.68) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.34 (5.88 - 11.62) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.29 (5.79 - 11.65) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.11 (5.58 - 11.44) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.9 (5.48 - 11.02) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.86 (5.32 - 10.96) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.88 (5.46 - 11.01) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8 (5.35 - 11.13) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.9 (5.33 - 11.01) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.85 (5.31 - 10.96) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.15 (5.38 - 11.41) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.35 (5.50 - 11.57) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.33 (5.39 - 11.73) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.37 (5.48 - 11.77) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HCV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 182 | 2016 | Modelled | WHO |
| 146 (94 - 205) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 146 (94 - 205) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 144 (94 - 203) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 142 (93 - 196) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 136 (90 - 190) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 131 (88 - 182) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 127 (86 - 178) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 124 (84 - 174) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 123 (83 - 171) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 121 (84 - 169) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 119 (83 - 166) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 120 (82 - 169) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 120 (84 - 169) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 119 (84 - 166) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 118 (84 - 164) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 116 (83 - 161) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 116 (83 - 161) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 116 (82 - 158) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 114 (82 - 154) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 115 (82 - 155) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 112 (81 - 151) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 110 (80 - 148) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 111 (80 - 149) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 110 (80 - 148) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 109 (78 - 147) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 108 (77 - 147) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 104 (74 - 141) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 102 (73 - 139) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 102 (73 - 140) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 101 (72 - 138) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 99 (70 - 136) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
Download
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 0 (0 - 0) | 2016 | Survey/reported | Harm Reduction International, 2016 |
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0 | 2016 | Survey/reported | Harm Reduction International, 2016 |
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
No
Eligible for HBV generic medicines
Overview
HBV elimination goal
HCV elimination goal
Prevalence (national)
Modelled
Survey/surveillance
No data available
Hepatitis related deaths (national)
Modelled
HBV
111
2019
(71 - 166)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HBV chart
Modelled
HCV
146
2019
(94 - 205)
IHME, GBD 2019 (accessed 2020)
Survey/surveillance
No data available
HCV chart
Prevalence < 5
HBV
2.12
(%)
2020, latest modelled
(1.78 - 2.48(%))
WHO
Prevalence PWID
No data available
Birth dose vaccination coverage (national)
Survey/surveillance
No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines